{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:31:57Z","timestamp":1793467917347,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Although anti-CD20 treatments are effective in inflammatory neurological diseases, they have some risks, especially infections. Determining the predictor factors of infection helps risk management in patients receiving anti-CD20 treatments. The effect of ocrelizumab (OCR) and rituximab (RTX) associated hypogammaglobulinemia (HGG) and lymphopenia on infection risk is controversial. The aim of this study to evaluate relationship between HGG and lymphocytopenia and infection risk and infection-related mortality in patients under RTX and OCR treatments and also compare these parameters between two agents. In our findings no relationship was found between HGG and infection risk in patients receiving OCR and RTX. In the RTX group, a significant relationship was detected between lymphocytopenia and severe infection. And, all three patients with infection-related mortality under rituximab treatment had HGG. No infection-related mortality was happened in OCR treatment. While lymphocytopenia and HGG were not detected as significant risk factors for infection, older age, female gender and &gt;\u20094 EDSS score were determined as risk factors for infection in patients receiving OCR treatment. Identifying factors predicting infection risk may provide better risk management in patients receiving anti-CD20 therapy.<\/jats:p>","DOI":"10.1007\/s10072-025-08329-x","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:25:13Z","timestamp":1751660713000},"page":"4569-4574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Secondary hypogammaglobulinemia and lymphocytopenia in patients with inflammatory neurological diseases on anti-CD20 therapy: risk of infection and infection-related mortality"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-1911","authenticated-orcid":false,"given":"Bedriye","family":"Karaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-569X","authenticated-orcid":false,"given":"G\u00f6ktu\u011f","family":"Din\u00e7er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-3366","authenticated-orcid":false,"given":"Rasim","family":"Tun\u00e7el","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-9416","authenticated-orcid":false,"given":"Ozgul","family":"Ekmekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-6423","authenticated-orcid":false,"given":"Nur","family":"Y\u00fcceyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"8329_CR1","doi-asserted-by":"publisher","first-page":"578066","DOI":"10.1016\/j.jneuroim.2023.578066","volume":"377","author":"V Mears","year":"2023","unstructured":"Mears V, Jakubecz C, Seeco C, Woodson S, Serra A, Abboud H (2023) Predictors of hypogammaglobulinemia and serious infections among patients receiving Ocrelizumab or rituximab for treatment of MS and NMOSD. J Neuroimmunol 377:578066","journal-title":"J Neuroimmunol"},{"issue":"11","key":"8329_CR2","doi-asserted-by":"publisher","first-page":"ofz445","DOI":"10.1093\/ofid\/ofz445","volume":"6","author":"E Zappulo","year":"2019","unstructured":"Zappulo E, Buonomo AR, Sacc\u00e0 F, Russo CV, Scotto R, Scalia G, Nozzolillo A, Lanzillo R, Tosone G, Gentile I (2019) Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis 6(11):ofz445","journal-title":"Open Forum Infect Dis"},{"key":"8329_CR3","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.msard.2021.102988","volume":"52","author":"NR Oksbjerg","year":"2021","unstructured":"Oksbjerg NR, Nielsen SD, Blinkenberg M, Magyari M, Sellebjerg F (2021) Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord 52:102988","journal-title":"Mult Scler Relat Disord"},{"key":"8329_CR4","doi-asserted-by":"crossref","unstructured":"Kim SH, Park NY, Kim KH, Hyun JW, Kim HJ (2022) Rituximab-Induced hypogammaglobulinemia and risk of infection in neuromyelitis Optica spectrum disorders: A 14-Year Real-Life experience. Neurol Neuroimmunol Neuroinflamm 9(5)","DOI":"10.1212\/NXI.0000000000001179"},{"issue":"5","key":"8329_CR5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","volume":"265","author":"EC Tallantyre","year":"2018","unstructured":"Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, Jacob A (2018) Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol 265(5):1115\u20131122","journal-title":"J Neurol"},{"issue":"7","key":"8329_CR6","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of Immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169","journal-title":"JAMA Netw Open"},{"key":"8329_CR7","doi-asserted-by":"crossref","unstructured":"Avouac A, Maarouf A, Stellmann JP, Rico A, Boutiere C, Demortiere S, Marignier R, Pelletier J, Audoin B (2021) Rituximab-Induced hypogammaglobulinemia and infections in AQP4 and MOG Antibody-Associated diseases. Neurol Neuroimmunol Neuroinflamm 8(3)","DOI":"10.1212\/NXI.0000000000000977"},{"issue":"3","key":"8329_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220","journal-title":"N Engl J Med"},{"key":"8329_CR9","doi-asserted-by":"crossref","unstructured":"Nobile S, Beauchemin P Hypogammaglobulinemia and infection risk in an Ocrelizumab-treated multiple sclerosis cohort. Can J Neurol Sci 2024:1\u20138","DOI":"10.1017\/cjn.2024.21"},{"issue":"8","key":"8329_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","volume":"35","author":"N Seery","year":"2021","unstructured":"Seery N, Sharmin S, Li V, Nguyen AL, Meaton C, Atvars R, Taylor N, Tunnell K, Carey J, Marriott MP et al (2021) Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: A retrospective cohort study. CNS Drugs 35(8):907\u2013918","journal-title":"CNS Drugs"},{"key":"8329_CR11","doi-asserted-by":"publisher","first-page":"103357","DOI":"10.1016\/j.msard.2021.103357","volume":"57","author":"A Dinoto","year":"2022","unstructured":"Dinoto A, Sartori A, Cheli M, Pasquin F, Baldini S, Bratina A, Bosco A, Manganotti P (2022) Lymphocytopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: prevalence, predicting factors and clinical outcomes. Mult Scler Relat Disord 57:103357","journal-title":"Mult Scler Relat Disord"},{"key":"8329_CR12","doi-asserted-by":"crossref","unstructured":"Klineova S, Lublin FD (2018) Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 8(9)","DOI":"10.1101\/cshperspect.a028928"},{"key":"8329_CR13","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM (2023) Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord 79:105009","journal-title":"Mult Scler Relat Disord"},{"key":"8329_CR14","doi-asserted-by":"publisher","first-page":"106191","DOI":"10.1016\/j.msard.2024.106191","volume":"93","author":"K Smolik","year":"2024","unstructured":"Smolik K, Camilli F, Panzera I, Fiore A, Franceschini A, Foschi M, Surcinelli A, Pesci I, Ferri C, Bazzurri V et al (2024) Hypogammaglobulinemia and severe infections in multiple sclerosis patients on anti-CD20 agents: A multicentre study. Mult Scler Relat Disord 93:106191","journal-title":"Mult Scler Relat Disord"},{"key":"8329_CR15","doi-asserted-by":"publisher","first-page":"1380654","DOI":"10.3389\/fneur.2024.1380654","volume":"15","author":"A Elgenidy","year":"2024","unstructured":"Elgenidy A, Abdelhalim NN, Al-Kurdi MA, Mohamed LA, Ghoneim MM, Fathy AW, Hassaan HK, Anan A, Alomari O (2024) Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients. Front Neurol 15:1380654","journal-title":"Front Neurol"},{"key":"8329_CR16","doi-asserted-by":"publisher","first-page":"1500763","DOI":"10.3389\/fneur.2024.1500763","volume":"15","author":"AA Fernandes","year":"2024","unstructured":"Fernandes AA, Neves AL, Ferro D, Seabra M, Mendonca T, Dos Reis RS, Sa MJ, Guimaraes J, Abreu P (2024) Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study. Front Neurol 15:1500763","journal-title":"Front Neurol"},{"issue":"7","key":"8329_CR17","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s00415-019-09690-6","volume":"268","author":"F Schweitzer","year":"2021","unstructured":"Schweitzer F, Laurent S, Fink GR, Barnett MH, Hartung HP, Warnke C (2021) Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. J Neurol 268(7):2379\u20132389","journal-title":"J Neurol"},{"key":"8329_CR18","doi-asserted-by":"publisher","first-page":"103740","DOI":"10.1016\/j.msard.2022.103740","volume":"60","author":"G Abbadessa","year":"2022","unstructured":"Abbadessa G, Maida E, Miele G, Lavorgna L, Marfia GA, Valentino P, De Martino A, Cavalla P, Bonavita S (2022) Lymphocytopenia in multiple sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells. Mult Scler Relat Disord 60:103740","journal-title":"Mult Scler Relat Disord"},{"key":"8329_CR19","doi-asserted-by":"publisher","first-page":"104400","DOI":"10.1016\/j.msard.2022.104400","volume":"68","author":"J Peters","year":"2022","unstructured":"Peters J, Longbrake EE (2022) Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord 68:104400","journal-title":"Mult Scler Relat Disord"},{"key":"8329_CR20","doi-asserted-by":"publisher","first-page":"103798","DOI":"10.1016\/j.msard.2022.103798","volume":"62","author":"M Habek","year":"2022","unstructured":"Habek M, Piska\u010d D, Gabeli\u0107 T, Barun B, Adamec I, Krbot Skori\u0107 M (2022) Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with Ocrelizumab. Mult Scler Relat Disord 62:103798","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"8329_CR21","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/13524585221079731","volume":"28","author":"SL Hauser","year":"2022","unstructured":"Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Sacc\u00e0 F, Mancione L, Zielman R et al (2022) Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler 28(10):1576\u20131590","journal-title":"Mult Scler"},{"issue":"5","key":"8329_CR22","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","volume":"44","author":"S Saidha","year":"2023","unstructured":"Saidha S, Bell J, Harold S, Belisario JM, Hawe E, Shao Q, Wyse K, Maiese EM (2023) Systematic literature review of Immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci 44(5):1515\u20131532","journal-title":"Neurol Sci"},{"key":"8329_CR23","doi-asserted-by":"publisher","first-page":"106191","DOI":"10.1016\/j.msard.2024.106191","volume":"93","author":"K Smolik","year":"2025","unstructured":"Smolik K, Camilli F, Panzera I, Fiore A, Franceschini A, Foschi M, Surcinelli A, Pesci I, Ferri C, Bazzurri V et al (2025) Hypogammaglobulinemia and severe infections in multiple sclerosis patients on anti-CD20 agents: A multicentre study. Mult Scler Relat Disord 93:106191","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08329-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:07:34Z","timestamp":1757207254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08329-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["8329"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08329-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All ethical principles and the Helsinki declaration were complied with during this study. The medical research ethics committee of Ege University Medical Faculty approved the research proposal (Number: 24-12T\/45).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}